Peginterferon alfa-2a (Pegasys) Coverage Criteria
Customize your policy alerts
Sign up for Peach State Health Plan Policy CP.PHAR.89 alerts
Get alerted when Policy CP.PHAR.89 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, coverage criteria, and authorization rules for peginterferon alfa-2a (Pegasys) across commercial, HIM/ICHRA, and Medicaid lines of business for Peach State Health Plan.
No material clinical or coverage changes in this revision.
Coverage Criteria
inv-01: Initial Approval — NCCN-Recommended Off-Label Indications
Covered when ALL of the following are met
Prescriber must submit supporting evidence when dose exceeds 3 mcg/kg/week
inv-02: Initial Approval — Chronic Hepatitis B (CHB)
Covered when ALL of the following are met
Prescribed regimen must be FDA‑approved or recommended by NCCN
inv-03: Continued Therapy — All Indications Except CHC
Covered when ALL of the following are met
Approval durations vary by line of business (see approval durations)
inv-04: Chronic Hepatitis B (CHB) Coverage
Covered when ALL of the following are met for CHB (as described in policy history and dosing):
Clarification added in policy history to align total CHB treatment period with existing approval duration
inv-05: NCCN-Recommended Off-Label Indications
NCCN-recommended off-label oncology indications (policy history indicates these exist and were modified over time):
Policy history revisions have added/clarified specific indications and monotherapy requirements; evidence of NCCN support required
Clarifying continuation durations added in policy history
The policy lists specific indications that are not authorized. These include treatment of chronic hepatitis C (CHC); uncontrolled autoimmune hepatitis; use following heart, lung, or kidney transplants; members with a prior history of drug or alcohol abuse who have not abstained for at least 3 months before starting therapy; and use solely to reduce risk of hepatocellular carcinoma in members with cirrhosis. Non‑FDA approved indications not addressed in this policy require documentation consistent with applicable off‑label use policies.
Per the AASLD/IDSA HCV guidance, interferon‑based regimens are no longer recommended for chronic hepatitis C (CHC) as of 2018 because they have been superseded by safe and effective direct‑acting antiviral (DAA) agents. Consequently, approval for PEG‑interferon for CHC is listed as Not applicable in this policy.
The policy states that interferon‑based regimens are no longer recommended for CHC consistent with the 2018 AASLD‑IDSA guidance; therefore, treatment of CHC with peginterferon is not authorized under this policy. Approval duration for CHC is documented as Not applicable.
Appendix D explicitly notes that the 2018 AASLD/IDSA Hepatitis C treatment guidelines state PEG‑interferon is not recommended for CHC because it has been superseded by regimens containing direct‑acting antivirals. When DAAs are appropriate, use of peginterferon alfa‑2a would therefore not be supported by this guidance and is not authorized by the policy.
Initial Therapy Criteria
inv-27: Initial therapy — Initial approval criteria vary by indication (NCCN off-label, CHB).
Initial approval criteria vary by indication (NCCN off‑label, CHB).
Initial approval duration for CHB aligns with approval duration and policy history clarifications
Initial approval durations for NCCN off‑label indications were revised by line of business in policy history
inv-28: Initial Therapy / Approval Durations
Initial approval durations and rules have been updated in policy history by line of business:
3Q 2026 clarification noted in policy history
See policy history for effective dates and lines of business
Continuation / Continued Therapy Criteria
inv-29: Continued therapy — Criteria for continued therapy for covered indications (excluding CHC).
Criteria for continued therapy for covered indications (excluding CHC).
Approval durations differ by line of business; see policy history for clarifications
inv-30: Continuation Therapy Durations
Continued therapy clarifications added in 3Q 2026 annual review:
Clarification added in 3Q 2026 to align with approval duration
Clarification added in 3Q 2026
Coding
Provider Actions & Requirements
Obtain prior authorization with supporting clinical evidence
Prior authorization is required for Pegasys. Submit supporting documentation demonstrating the member meets the specific approval criteria for the requested indication (e.g., NCCN off‑label criteria or CHB lab/biopsy thresholds and specialist consultation).
Confirm PA approval durations by line of business
Prior authorization rules and approval durations vary by indication and line of business; review the policy history for specific approval durations (Commercial, Medicaid, HIM/ICHRA) as these have been revised over time.
- Examples in policy history: non‑Commercial NCCN off‑label initial approvals revised from 6 to 12 months; Commercial non‑CHC approvals revised to 6 months or to member renewal date, whichever is longer.
- CHB clarifications limit total treatment period to ≤ 48 weeks.
Off‑label oncology: oncologist involvement and dose limits
For NCCN‑recommended off‑label oncology indications, the prescriber must be the oncologist or consult with one, and dosing must not exceed 3 mcg/kg per week unless supported by practice guidelines or peer‑reviewed literature (prescriber must submit evidence if exceeding).
- Dose > 3 mcg/kg/week requires supporting evidence in the request.
CHC step consideration — DAAs preferred; PEG‑interferon not recommended
For chronic hepatitis C (CHC) requests: recognize that AASLD/IDSA guidance no longer recommends PEG‑interferon for CHC because direct‑acting antivirals supersede interferon‑based regimens; this supports exclusion/step pathways favoring DAAs where appropriate.
- CHC treatment with peginterferon is listed among diagnoses for which coverage is NOT authorized.
Submit required clinical documentation with PA request
Provider must submit documentation (office chart notes, lab results, or other clinical information) that the member meets all approval criteria when requesting authorization.
- Include specialist consultation notes when required (oncology for off‑label oncology uses; gastroenterology/hepatology/ID for CHB).
- Include relevant labs (e.g., two ALT values, HBV DNA) or biopsy reports for CHB criteria.
Follow product labeling and guideline-based supporting documentation
Prescribing should follow the product labeling and referenced guidelines (Pegasys Prescribing Information and AASLD/IDSA guidance); include citations or PI excerpts when relevant to support dosing or indication decisions.
- Reference Pegasys PI (Dailymed) and NCCN or AASLD/IDSA guidance in the request when applicable.
Denial risk: CHC and non‑addressed off‑label indications
Requests to treat chronic hepatitis C (CHC) with Pegasys are not authorized per this policy; non‑listed off‑label uses require adherence to the applicable off‑label use policies and sufficient documentation of efficacy and safety.
- For non‑FDA indications not addressed by this policy, submit evidence per off‑label use policies CP.CPA.09 (Commercial), HIM.PA.154 (HIM/ICHRA), or CP.PMN.53 (Medicaid).
Coding reminder — verify coding before claim submission
Inclusion or exclusion of listed codes is informational only and does not guarantee coverage; providers should verify current professional coding guidance prior to claim submission.
Step Therapy
| Step | Requirement |
|---|---|
| 1 | |
| Prescriber must be the patient’s oncologist or consult with an oncologist; dose must not exceed 3 mcg/kg per week unless the higher dose is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence). |
| Step | Requirement |
|---|---|
| 1 | |
| For chronic hepatitis C (CHC), direct-acting antivirals (DAAs) are preferred per AASLD/IDSA guidance; PEG-interferon is not recommended for CHC and should not be used when DAAs are appropriate. |
Quantity Limits & Product
Site of Care
Subcutaneous (SC) administration per product labeling; weekly dosing
Administer subcutaneously per product labeling; dosing for CHB is described as 180 mcg SC once weekly in adults (pediatric dosing per PI).
- Product presentations: vial 180 mcg/mL and prefilled syringe 180 mcg/0.5 mL.
Definitions
Background
Peginterferon alfa‑2a (Pegasys) is a pegylated recombinant interferon alfa‑2a indicated in this policy for select viral hepatitis and certain hematologic/oncologic conditions. The policy clarifies that interferon‑based regimens have been superseded for chronic hepatitis C by direct‑acting antivirals per the 2018 AASLD/IDSA guidance, and therefore CHC treatment with Pegasys is not authorized. For other covered uses (for example chronic hepatitis B and selected NCCN‑recommended off‑label oncology indications), the policy requires specialist involvement, defined laboratory or biopsy thresholds, adherence to dosing limits, and prior authorization with supporting documentation.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.